Logo-ijhpm
Commentary

1. New Health Technologies: A UK Perspective Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
Nassim Parvizi*, Sahar Parvizi
Int J Health Policy Manag. 2017;6(12): 721-722. doi: 10.15171/ijhpm.2017.59
PMCID: PMC5726322     PMID: 29172379    
Article
PDF
XML
Cited By:
Commentary

2. The Bright Elusive Butterfly of Value in Health Technology Development Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
Trisha Greenhalgh*, Nick Fahy, Sara Shaw
Int J Health Policy Manag. 2018;7(1): 81-85. doi: 10.15171/ijhpm.2017.65
PMCID: PMC5745872     PMID: 29325407    
Article
PDF
XML
Cited By:
Original Article

3. Evaluation of Transition to Electronic Prescriptions in Turkey: Perspective of Family Physicians 
Sinan Bulut*, Ahmet Yıldız, Sıdıka Kaya
Int J Health Policy Manag. 2019;8(1): 40-48. doi: 10.15171/ijhpm.2018.89
PMCID: PMC6358642     PMID: 30709101    
Article
PDF
XML
Cited By:
Commentary

4. Disease Control Priorities Third Edition: Time to Put a Theory of Change Into Practice Comment on “Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy”
Wanrudee Isaranuwatchai, Ryan Li, Amanda Glassman, Yot Teerawattananon, Anthony J. Culye, Kalipso Chalkidou*
Int J Health Policy Manag. 2019;8(2): 132-135. doi: 10.15171/ijhpm.2018.115
PMCID: PMC6462203     PMID: 30980627    
Article
PDF
XML
Cited By:
Original Article

5. Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling
Janneke P.C. Grutters* ORCID, Tim Govers ORCID, Jorte Nijboer Nijboer, Marcia Tummers ORCID, Gert Jan van der Wilt ORCID, Maroeska M. Rovers
Int J Health Policy Manag. 2019;8(10): 575-582. doi: 10.15171/ijhpm.2019.36
PMCID: PMC6819627     PMID: 31657184    
Article
PDF
Suppl 1
Suppl 2
XML
Cited By:
Commentary

6. Nurturing Societal Values in and Through Health Innovations Comment on “What Health System Challenges Should Responsible Innovation in Health Address?” 
Payam Abrishami*, Sjoerd Repping ORCID
Int J Health Policy Manag. 2019;8(10): 613-615. doi: 10.15171/ijhpm.2019.57
PMCID: PMC6819623     PMID: 31657189    
Article
PDF
XML
Cited By:
Commentary

7. Modeling in Early Stages of Technology Development: Is an Iterative Approach Needed? Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling”
Michael F. Drummond*
Int J Health Policy Manag. 2020;9(6): 260-262. doi: 10.15171/ijhpm.2019.118
PMCID: PMC7382911     PMID: 32613795    
Article
PDF
XML
Cited By:
Commentary

8. Use of Evidence-Informed Deliberative Processes – Learning by Doing Comment on “Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe”
Anthony J. Culyer* ORCID
Int J Health Policy Manag. 2020;9(6): 263-265. doi: 10.15171/ijhpm.2019.116
PMCID: PMC7382906     PMID: 32613796    
Article
PDF
XML
Cited By:
Commentary

9. Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling”
Nadine K. Zawadzki* ORCID, Joel W. Hay ORCID
Int J Health Policy Manag. 2020;9(8): 352-355. doi: 10.15171/ijhpm.2019.132
PMCID: PMC7500389     PMID: 32613807    
Article
PDF
XML
Cited By:
Original Article

10. Comparing 3 Approaches for Making Vaccine Adoption Decisions in Thailand
Waranya Rattanavipapong* ORCID, Ritika Kapoor, Yot Teerawattananon, Jos Luttjeboer, Siobhan Botwright, Rachel A. Archer, Birgitte Giersing, Raymond C. W. Hutubessy
Int J Health Policy Manag. 2020;9(10): 439-447. doi: 10.15171/ijhpm.2020.01
PMCID: PMC7719214     PMID: 32610741    
Article
PDF
Suppl 1
Suppl 2
XML
Cited By:
Commentary

11. Early Health Economic Modelling – Optimizing Development for Medical Device Developers? Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling”
Conor Teljeur*, Máirín Ryan
Int J Health Policy Manag. 2020;9(9): 403-405. doi: 10.15171/ijhpm.2019.136
PMCID: PMC7557429     PMID: 32610765    
Article
PDF
XML
Cited By:
Commentary

12. The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling”
Hansoo Kim* ORCID, Stephen Goodall, Danny Liew
Int J Health Policy Manag. 2021;10(2): 98-101. doi: 10.15171/ijhpm.2020.17
PMCID: PMC7947661     PMID: 32610777    
Article
PDF
XML
Cited By:
Commentary

13. Expanding the Role of Early Health Economic Modelling in Evaluation of Health Technologies Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling”
Carlo Federici ORCID, Aleksandra Torbica* ORCID
Int J Health Policy Manag. 2021;10(2): 102-105. doi: 10.15171/ijhpm.2020.18
PMCID: PMC7947662     PMID: 32610778    
Article
PDF
XML
Cited By:
Commentary

14. Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on “Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe”
Mireille Goetghebeur* ORCID, Marjo Cellier
Int J Health Policy Manag. 2021;10(4): 228-231. doi: 10.34172/ijhpm.2020.46
PMCID: PMC8167272     PMID: 32610794    
Article
PDF
XML
Cited By:
Original Article

15. A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
Magdalena Bujar* ORCID, Neil McAuslane, Stuart Walker, Sam Salek
Int J Health Policy Manag. 2022;11(2): 128-137. doi: 10.34172/ijhpm.2020.86
PMCID: PMC9278608     PMID: 32610811    
Article
PDF
Suppl 1
Suppl 2
XML
Cited By:
Short Communication

16. Experiences of Using Cochrane Systematic Reviews by Local HTA Units
Thomas G. Poder* ORCID, Marc Rhainds ORCID, Christian A. Bellemare ORCID, Simon Deblois ORCID, Imane Hammana ORCID, Catherine Safianyk ORCID, Sylvie St-Jacques ORCID, Pierre Dagenais ORCID
Int J Health Policy Manag. 2022;11(2): 112-117. doi: 10.34172/ijhpm.2020.133
PMCID: PMC9278610     PMID: 32772006    
Article
PDF
XML
Cited By:
Commentary

17. Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on “Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe”

Unni Gopinathan* ORCID, Trygve Ottersen, Pascale-Renée Cyr, Kalipso Chalkidou ORCID
Int J Health Policy Manag. 2021;10(4): 232-236. doi: 10.34172/ijhpm.2020.145
PMCID: PMC8167266     PMID: 32772012    
Article
PDF
XML
Cited By:
Original Article

18. Ethical and Social Values for Paediatric Health Technology Assessment and Drug Policy
Avram E. Denburg* ORCID, Mita Giacomini, Wendy Ungar, Julia Abelson ORCID
Int J Health Policy Manag. 2022;11(3): 374-382. doi: 10.34172/ijhpm.2020.144
PMCID: PMC9278467     PMID: 32801223    
Article
PDF
XML
Cited By:
Original Article

19. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
Rick A. Vreman ORCID, Lourens T. Bloem ORCID, Stijn van Oirschot, Jarno Hoekman, Menno E. van der Elst, Hubert GM Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel-Teeuwisse* ORCID
Int J Health Policy Manag. 2022;11(5): 642-650. doi: 10.34172/ijhpm.2020.198
PMCID: PMC9309934     PMID: 33131224    
Article
PDF
Suppl 1
XML
Cited By:
Original Article

20. Evidence-Informed Deliberative Processes for Legitimate Health Benefit Package Design − Part I: Conceptual Framework
Rob Baltussen* ORCID, Maarten Jansen ORCID, Wija Oortwijn ORCID
Int J Health Policy Manag. 2022;11(10): 2319-2326. doi: 10.34172/ijhpm.2021.158
PMCID: PMC9808261     PMID: 34923808    
Article
PDF
XML
Cited By:
Original Article

21. Evidence-Informed Deliberative Processes for Health Benefit Package Design – Part II: A Practical Guide
Wija Oortwijn* ORCID, Maarten Jansen ORCID, Rob Baltussen ORCID
Int J Health Policy Manag. 2022;11(10): 2327-2336. doi: 10.34172/ijhpm.2021.159
PMCID: PMC9808268     PMID: 34923809    
Article
PDF
Suppl 1
XML
Cited By:
Commentary

22. Challenges and Opportunities for Deliberative Processes for Healthcare Decision-Making Comment on “Evidence-Informed Deliberative Processes for Health Benefit Package Design – Part II: A Practical Guide”

Kenneth Bond* ORCID
Int J Health Policy Manag. 2023;12: 7458 | Published on: 2022 Aug 16. doi: 10.34172/ijhpm.2022.7458
PMCID: PMC10125176     PMID: 35988028    
Article
PDF
XML
Cited By:
Commentary

23. Three Approaches to Improve a Practical Guide on Evidence-Informed Deliberative Processes for Health Benefit Package Design Comment on “Evidence-Informed Deliberative Processes for Health Benefit Package Design – Part II: A Practical Guide”

Javier Guzman* ORCID
Int J Health Policy Manag. 2023;12: 7502 | Published on: 2022 Aug 31. doi: 10.34172/ijhpm.2022.7502
PMCID: PMC10125080     PMID: 36086853    
Article
PDF
XML
Cited By:
Commentary

24. Moral and Social Values in Evidence-Informed Deliberative Processes for Health Benefit Package Design Comment on “Evidence-Informed Deliberative Processes for Health Benefit Package Design – Part II: A Practical Guide”
Michael J. DiStefano* ORCID
Int J Health Policy Manag. 2023;12: 7480 | Published on: 2022 Dec 28. doi: 10.34172/ijhpm.2022.7480
PMCID: PMC10125053     PMID: 37579447    
Article
PDF
XML
Cited By:
Commentary

25. Evidence-Informed Deliberative Processes for UHC: Progress, Potential and Prudence Comment on “Evidence-Informed Deliberative Processes for Health Benefit Package Design – Part II: A Practical Guide”

Unni Gopinathan* ORCID
Int J Health Policy Manag. 2023;12: 7541 | Published on: 2023 Feb 13. doi: 10.34172/ijhpm.2022.7541
PMCID: PMC10125249     PMID: 37579471    
Article
PDF
XML
Cited By:
Original Article

26. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward
Sarin Kc ORCID, Lydia Wenxin Lin, Diana Beatriz Samson Bayani, Yaroslava Zemlyanska ORCID, Amanda Adler, Jeonghoon Ahn, Kelvin Chan, Dechen Choiphel, Anne Julienne Genuino-Marfori, Brendon Kearney, Yuehua Liu, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh-Fang Pwu, Arsul Akmal Shafie ORCID, Binyan Sui, Auliya Suwantika ORCID, Sean Tunis, Hui-Min Wu, John Zalcberg, Kun Zhao, Wanrudee Isaranuwatchai ORCID, Yot Teerawattananon ORCID, Hwee-Lin Wee* ORCID
Int J Health Policy Manag. 2023;12: 6858 | Published on: 2023 Mar 06. doi: 10.34172/ijhpm.2023.6858
PMCID: PMC10461954     PMID: 37579427    
Article
PDF
XML
Cited By:
Original Article

27. Assessing Global Evidence on Cost-Effectiveness to Inform Development of Pakistan’s Essential Package of Health Services
Maryam Huda ORCID, Nichola Kitson, Nuru Saadi, Saira Kanwal, Urooj Gul, Maarten Jansen ORCID, Sergio Torres-Rueda ORCID, Rob Baltussen ORCID, Ala Alwan ORCID, Sameen Siddiqi ORCID, Anna Vassall* ORCID
Int J Health Policy Manag. 2024;13: 8005 | Published on: 2024 Jan 07. doi: 10.34172/ijhpm.2023.8005
Article
PDF
Suppl 1
Suppl 2
XML
Cited By:
Systematic Review

28. Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review
Daniel E. Wang ORCID, Maram Hassanein, Yasmeen Razvi, Randi Zlotnik Shaul, Avram Denburg* ORCID
Int J Health Policy Manag. 2024;13: 7494 | Published on: 2024 Feb 10. doi: 10.34172/ijhpm.2024.7494
PMCID: PMC11016276     PMID: 38618836    
Article
PDF
Suppl 1
Suppl 2
Suppl 3
XML
Cited By: